The prevention of contrast induced nephropathy by sarpogrelate in patients with chronic kidney disease: A study protocol for a prospective randomized controlled clinical trial

Trials

Volumn 11, Issue , 2010, Pages

  Park, Kyungil ^a,c   Chung, Woo Young ^a,b   Seo, Jae Bin ^a,b   Kim, Sang Hyun ^a,b   Zo, Joo Hee ^a,b   Kim, Myung A ^a,b   Park, Young Bae ^a,c  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Boramae Hospital   (South Korea)

^c Seoul National University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; SARPOGRELATE; SEROTONIN 2 ANTAGONIST; SUCCINIC ACID DERIVATIVE;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CHRONIC DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; CONTRAST; CONTRAST INDUCED NEPHROPATHY; CONTROLLED STUDY; ELECTRIC POTENTIAL; FEMALE; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PREMEDICATION; PROSPECTIVE STUDY; REGISTRATION; SAFETY; CHEMICALLY INDUCED DISORDER; CLINICAL PROTOCOL; CONTROLLED CLINICAL TRIAL; METHODOLOGY; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; CHRONIC DISEASE; CLINICAL PROTOCOLS; CONTRAST MEDIA; HUMANS; KIDNEY DISEASES; MIDDLE AGED; PROSPECTIVE STUDIES; RESEARCH DESIGN; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS; SUCCINATES; YOUNG ADULT;

EID: 78650301200     PISSN: 17456215     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-11-122     Document Type: Article

References (30)

1. Weisbord SD, Chen H, Stone RA, Kip KE, Fine MJ, Saul MI, Palevsky PM. Associations of increases in serum creatinine with mortality and length of hospital stay after coronary angiography. J Am Soc Nephrol 2006, 17:2871-2877. 10.1681/ASN.2006030301, 16928802.
2. Gruberg L, Mintz GS, Mehran R, Gangas G, Lansky AJ, Kent KM, Pichard AD, Satler LF, Leon MB. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol 2000, 36:1542-1548. 10.1016/S0735-1097(00)00917-7, 11079656.
3. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997, 103:368-375. 10.1016/S0002-9343(97)00150-2, 9375704.
4. Rudnick MR, Berns JS, Cohen RM, Goldfarb S. Contrast media-associated nephrotoxicity. Semin Nephrol 1997, 17:15-26.
5. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, Singh M, Bell MR, Barsness GW, Mathew V, Garratt KN, Holmes DR. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002, 105:2259-2264. 10.1161/01.CIR.0000016043.87291.33, 12010907.
6. Merten GJ, Burgess WP, Gray LV, Holleman JH, Roush TS, Kowalchuk GJ, Bersin RM, Van Moore A, Simonton CA, Rittase RA, Norton HJ, Kennedy TP. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 2004, 291:2328-2334. 10.1001/jama.291.19.2328, 15150204.
7. Kay J, Chow WH, Chan TM, Lo SK, Kwok OH, Yip A, Fan K, Lee CH, Lam WF. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA 2003, 289:553-558. 10.1001/jama.289.5.553, 12578487.
8. Erley CM, Duda SH, Rehfuss D, Scholtes B, Bock J, Müller C, Osswald H, Risler T. Prevention of radiocontrast-media-induced nephropathy in patients with pre-existing renal insufficiency by hydration in combination with the adenosine antagonist theophylline. Nephrol Dial Transplant 1999, 4:1146-114.
9. Stacul F, Adam A, Becker CR, Davidson C, Lameire N, McCullough PA, Tumlin J, . CIN Consensus Working Panel Strategies to reduce the risk of contrast-induced nephropathy. Am J Cardiol 2006, 98:59-77. CIN Consensus Working Panel.
10. Rudnick MR, Kesselheim A, Goldfarb S. Contrast-induced nephropathy: how it develops, how to prevent it. Cleve Clin J Med 2006, 73:75-87. 10.3949/ccjm.73.1.75, 16444919.
11. Recio-Mayoral A, Chaparro M, Prado B, Cózar R, Méndez I, Banerjee D, Kaski JC, Cubero J, Cruz JM. The reno-protective effect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percutaneous coronary intervention: the RENO Study. J Am Coll Cardiol 2007, 49:1283-1288. 10.1016/j.jacc.2006.11.034, 17394959.
12. Masuda M, Yamada T, Mine T, Morita T, Tamaki S, Tsukamoto Y, Okuda K, Iwasaki Y, Hori M, Fukunami M. Comparison of usefulness of sodium bicarbonate versus sodium chloride to prevent contrast-induced nephropathy in patients undergoing an emergent coronary procedure. Am J Cardiol 2007, 100:781-786. 10.1016/j.amjcard.2007.03.098, 17719320.
13. Katzberg RW, Morris TW, Burgener FA, Kamm DE, Fischer HW. Renal renin and hemodynamic responses to selective renal artery catheterization and angiography. Invest Radiol 1977, 12:381-388. 10.1097/00004424-197709000-00002, 914484.
14. Heyman SN, Brezis M, Epstein FH, Spokes K, Silva P, Rosen S. Early renal medullary hypoxic injury from radiocontrast and indomethacin. Kidney Int 1991, 40:632-642. 10.1038/ki.1991.255, 1745012.
15. Heyman SN, Brezis M, Reubinoff CA, Greenfeld Z, Lechene C, Epstein FH, Rosen S. Acute renal failure with selective medullary injury in the rat. J Clin Invest 1988, 82:401-412. 10.1172/JCI113612, 303528, 3403711.
16. Hara H, Kitajima A, Shimada H, Tamao Y. Antithrombotic effect of MCI-9042, a new antiplatelet agent on experimental thrombosis models. Thromb Haemost 1991, 66:484-488.
17. Miyata K, Shimokawa H, Higo T, Yamawaki T, Katsumata N, Kandabashi T, Tanaka E, Takamura Y, Yogo K, Egashira K, Takeshita A. Sarpogrelate, a selective 5-HT2A serotonergic receptor antagonist, inhibits serotonin-induced coronary artery spasm in a porcine model. J Cardiovasc Pharmacol 2000, 35:294-301. 10.1097/00005344-200002000-00018, 10672864.
18. Sharma SK, Zahradka P, Chapman D, Kumamoto H, Takeda N, Dhalla NS. Inhibition of serotonin-induced vascular smooth muscle cell proliferation by sarpogrelate. J Pharmacol Exp Ther 1999, 290:1475-1481.
19. Hayashi T, Sumi D, Matsui-Hirai H, Fukatsu A, Arockia Rani PJ, Kano H, Tsunekawa T, Iguchi A. Sarpogrelate HCl, a selective 5-HT2A antagonist, retards the progression of atherosclerosis through a novel mechanism. Atherosclerosis 2003, 168:23-31. 10.1016/S0021-9150(03)00054-6, 12732383.
20. Fujita M, Mizuno K, Ho M, Tsukahara R, Miyamoto A, Miki O, Ishii K, Miwa K. Sarpogrelate treatment reduces restenosis after coronary stenting. Am Heart J 2003, 145:E16. 10.1067/mhj.2003.176, 12660685.
21. Hara H, Shimada H, Kitajima A, Tamao Y. Effect of (+/-)-2-(dimethylamino)-1-[[o-(m-methoxyphenethyl)phenoxy] methyl]ethyl hydrogen succinate on experimental models of peripheral obstructive disease. Arzneimittelforschung 1991, 41:616-620.
22. Ichiyanagi N, Tsujii T, Masuda H, Kihara K, Goto M, Azuma H. Changed responsiveness of the detrusor in rabbits with alloxan induced hyperglycemia: possible role of 5-hydroxytryptamine for diabetic bladder dysfunction. J Urol 2002, 168:303-307. 10.1016/S0022-5347(05)64912-9, 12050561.
23. Kanai H, Hiromura K, Kuroiwa T, Maezawa A, Yano S, Naruse T. Role of serotonin in nephrotoxic serum nephritis in WKY rats. J Lab Clin Med 1997, 129:557-566. 10.1016/S0022-2143(97)90010-X, 9142052.
24. Doggrell SA. The role of 5-HT on the cardiovascular and renal systems and the clinical potential of 5-HT modulation. Expert Opin Investig Drugs 2003, 12:805-823. 10.1517/13543784.12.5.805, 12720492.
25. Ishimura E, Nishizawa Y, Emoto M, Shoji T, Inaba M, Kawagishi T, Morii H. Therapeutic effect of sarpogrelate, a new 5-hydroxytryptamine receptor 2A antagonist, on diabetic nephropathy and neuropathy. Nephron 1997, 76:227-229. 10.1159/000190175, 9200418.
26. Ogawa S, Takeuchi K, Sugimura K, Sato C, Fukuda M, Lee R, Ito S, Sato T. The 5-HT2 receptor antagonist sarpogrelate reduces urinary and plasma levels of thromboxane A2 and urinary albumin excretion in non-insulin-dependent diabetes mellitus patients. Clin Exp Pharmacol Physiol 1999, 26:461-464. 10.1111/j.1440-1681.1999.03056.x, 10386239.
27. Takahashi T, Yano M, Minami J, Haraguchi T, Koga N, Higashi K, Kobori S. Sarpogrelate hydrochloride, a serotonin2A receptor antagonist, reduces albuminuria in diabetic patients with early-stage diabetic nephropathy. Diabetes Res Clin Pract 2002, 58:123-129. 10.1016/S0168-8227(02)00105-5, 12213354.
28. Morcos SK, Thomsen HS, Webb JA. Contrast-media-induced nephrotoxicity: a consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR). Eur Radiol 1999, 9:1602-1613. 10.1007/s003300050894, 10525875.
29. Nikolsky E, Aymong ED, Dangas G, Mehran R. Radiocontrast nephropathy: identifying the high-risk patient and the implications of exacerbating renal function. Rev Cardiovasc Med 2003, 4(Suppl 1):S7-S14.
30. The GUSTO Investigators An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993, 329:673-682. 10.1056/NEJM199309023291001, 8204123, The GUSTO Investigators.